- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04097197
Factors Influencing Flu Vaccination in Primary Health Care (FIVA)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
People from vulnerable groups (e.g., those diagnosed with Diabetes, Chronic Obstructive Pulmonary Disease, Asthma) are at increased risk of developing complications from infection with influenza virus, that could ultimately result in death.
Flu vaccination is recommended by many authorities, including the World Health Organization, as a means to decrease the risk of developing such life-threatening conditions. However, vaccination rates are well below the recommended threshold.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Dão Lafões
-
Viseu, Dão Lafões, Portugal, 3514-511
- Dão Lafões Grouping of Primary Health Care Centres
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- People 65+ otherwise healthy;
- Patients of any age diagnosed with at least one of the following conditions: Diabetes, Asthma, COPD, Coronary Disease or Hearth failure;
- No history of flu vaccination in the previous year.
Exclusion Criteria:
- Patients who have been vaccinated against the flu but who have no record of it in the clinical records;
- Patients with contraindications to flu vaccination;
- Patients that cannot be reached either by phone or letter.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients receiving information
Patients in the experimental arm will receive a brief educational intervention if they initially refuse flu vaccination.
The intervention was designed towards the most common barriers to flu vaccination that were found after a brief review of the literature.
After the intervention, patients will be asked again whether or not they wish to receive the flu vaccine.
|
same as before
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Flu vaccination refusal rate
Time Frame: up to 6 months
|
Percentage of patients refusing flu vaccination prior to intervention
|
up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of barriers to flu vaccination
Time Frame: up to 6 months
|
Percentage of participants mentioning a determined barrier to flu vaccination
|
up to 6 months
|
Flu vaccination acceptance rate post-intervention
Time Frame: up to 6 months
|
Percentage of patients who accept receiving the flu vaccine after receiving the intervention
|
up to 6 months
|
Flu vaccination rate
Time Frame: up to 6 months
|
Percentage of patients who have been vaccinated after the intervention
|
up to 6 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FIVA_2019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Flu, Human
-
SeqirusNovartis VaccinesCompletedInfluenza | Influenza, Human | Influenza A Virus, H5N1 Subtype | Flu, Human | Flu, AvianAustralia, Germany, Italy
-
Hospital de Clinicas de Porto AlegreCompleted
-
Advagene Biopharma Co. Ltd.National Taiwan University HospitalCompleted
-
Harvard UniversityNational Institute on Aging (NIA); Massachusetts Institute of Technology; Ludwig-Maximilians...CompletedCovid19 | Influenza, Human | Flu, HumanUnited States
-
Aarogyam UKCompletedFlu Like Symptom | Flu Like IllnessUnited Kingdom
-
University of PennsylvaniaNational Institute on Aging (NIA); University of WashingtonActive, not recruitingFlu | Behavior, Health | Flu VaccinationUnited States
-
St. Petersburg Research Institute of Vaccines and...CompletedInfluenza | Flu, HumanRussian Federation
-
Brigham and Women's HospitalDepartment of Health and Human Services; Centers for Medicare and Medicaid... and other collaboratorsCompletedInfluenza | Influenza, Human | Human FluUnited States
-
Dove Medical Press LtdThe Affiliated Hospital of Qingdao UniversityCompletedBacterial Growth | Novel Influenza A (H1N1)China
-
Kemin Foods LCKGK Science Inc.CompletedStress | Flu | Cold | Flu Symptom | Cold Symptom | Gastrointestinal Tolerance | SupplementCanada
Clinical Trials on Brief educational intervention
-
Boston Children's HospitalConrad N. Hilton FoundationCompletedSubstance UseUnited States
-
University of Missouri-ColumbiaCompletedPhysical Inactivity | Poor DietUnited States
-
Haukeland University HospitalCompleted
-
Philipps University Marburg Medical CenterAstraZenecaUnknownDepression | Chronic Obstructive Pulmonary Disease | End-of-Life Fear | Fear About Death and DyingGermany
-
Institut Català d'OncologiaHospital Clinic of Barcelona; Hospital Universitari de Bellvitge; Fundació Institut... and other collaboratorsCompletedSmoking Cessation | Motivation | Mental DisorderSpain
-
Seattle Children's HospitalEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedTrust | Respect | Study EnrollmentUnited States
-
University of California, Los AngelesUnknownCovid-19 | Critical Illness | Health Behavior | Health Care Utilization | Attitude of Health Personnel | Attitude to HealthUnited States
-
Sykehuset Innlandet HFUniversity of BergenCompletedMusculoskeletal DiseasesNorway
-
Gary MorrowNational Cancer Institute (NCI); Stanford UniversityCompletedSleep Disorder | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of North Carolina, Chapel HillNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Failure, CongestiveUnited States